Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Health Catalyst (HCAT) Other Non-Current Liabilities (2018 - 2025)

Health Catalyst's Other Non-Current Liabilities history spans 8 years, with the latest figure at $250000.0 for Q4 2025.

  • For Q4 2025, Other Non-Current Liabilities changed N/A year-over-year to $250000.0; the TTM value through Dec 2025 reached $250000.0, changed N/A, while the annual FY2025 figure was $250000.0, N/A changed from the prior year.
  • Other Non-Current Liabilities reached $250000.0 in Q4 2025 per HCAT's latest filing, up from $40000.0 in the prior quarter.
  • In the past five years, Other Non-Current Liabilities ranged from a high of $8.3 million in Q1 2021 to a low of $40000.0 in Q3 2025.
  • Average Other Non-Current Liabilities over 5 years is $1.1 million, with a median of $122000.0 recorded in 2022.
  • Peak YoY movement for Other Non-Current Liabilities: plummeted 99.33% in 2021, then soared 4550.68% in 2024.
  • A 5-year view of Other Non-Current Liabilities shows it stood at $113000.0 in 2021, then increased by 7.08% to $121000.0 in 2022, then tumbled by 38.84% to $74000.0 in 2023, then surged by 4487.84% to $3.4 million in 2024, then crashed by 92.64% to $250000.0 in 2025.
  • Per Business Quant, the three most recent readings for HCAT's Other Non-Current Liabilities are $250000.0 (Q4 2025), $40000.0 (Q3 2025), and $2.1 million (Q2 2025).